Article
The clinical efficacy of Afatinib 30 mg daily as starting dose may not be inferior to Afatinib 40 mg daily in patients with stage IV lung Adenocarcinoma harboring exon 19 or exon 21 mutations.
BMC pharmacology & toxicology - 13 Dec 2017
Yang Chih-Jen, Tsai Ming-Ju, Hung Jen-Yu, Lee Mei-Hsuan, Tsai Ying-Ming, Tsai Yu-Chen, Hsu Jui-Feng, Liu Ta-Chih, Huang Ming-Shyan, Chong Inn-Wen
Abstract excerpt
BACKGROUND: Afatinib is a second-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI). Compared to cytotoxic chemotherapy, afatinib has been shown to have better efficacy in the treatment of non-small cell lung cancer harboring EGFR mutations. However, 40 mg daily as the initial dose is often accompanied by serious adverse drug reactions (ADRs) and 28 to 53.3% of patients required a...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.